[Correspondence] Questionable efficacy of the rVSV-ZEBOV Ebola vaccine

We read with great interest the final report by Ana Maria Henao-Restrepo and colleagues (Feb 4, 2017, p 505)1 on the ring vaccination trial of an rVSV-vectored vaccine for Ebola virus disease (rVSV-ZEBOV). Briefly, among 2119 people who received the vaccine immediately, no cases of Ebola virus disease were identified in a period of 11 days (10 –21 days after vaccination). By contrast, 16 cases were identified within the same time frame among 2041 people who did not receive the vaccine immediately.
Source: LANCET - Category: General Medicine Authors: Tags: Correspondence Source Type: research